Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Current Liabilities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Total Current Liabilities for 3 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 6.81% to $13.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.1 million, a 6.81% increase, with the full-year FY2025 number at $13.1 million, up 6.81% from a year prior.
  • Total Current Liabilities was $13.1 million for Q4 2025 at Artiva Biotherapeutics, up from $11.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $13.3 million in Q3 2024 to a low of $10.8 million in Q2 2025.
  • A 3-year average of $12.0 million and a median of $12.2 million in 2023 define the central range for Total Current Liabilities.
  • Biggest YoY gain for Total Current Liabilities was 6.81% in 2025; the steepest drop was 16.35% in 2025.
  • Artiva Biotherapeutics' Total Current Liabilities stood at $12.2 million in 2023, then increased by 0.21% to $12.3 million in 2024, then grew by 6.81% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Total Current Liabilities are $13.1 million (Q4 2025), $11.1 million (Q3 2025), and $10.8 million (Q2 2025).